Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.

Accumulations of glycosaminoglycans (GAGs) that result from deficiencies in lysosomal hydrolases are characteristic of mucopolysaccharidoses (MPS). Enzyme replacement therapies (ERTs) are now available for several MPS diseases (MPS I, MPS II, MPS IVA, MPS VI, and MPS VII), but assessment of the efficacy of treatment can be challenging because these are rare, progressive, and highly heterogeneous diseases; because some clinical manifestations may be irreversible if treatment initiation is delayed; and because determining the benefits of a treatment to prevent those manifestations may take prolonged periods of time. In addition to accumulation of GAGs in tissues, elevated urinary GAG (uGAG) levels are evident and are reduced rapidly after initiation of ERT. Studies in MPS animal models and clinical studies in subjects with MPS diseases have revealed correlations between reductions of uGAG levels and clinical effects of ERTs. In this article, we review the growing body of evidence to support the potential for the use of uGAG levels as predictive biomarkers of treatment efficacy.

• Publication year

  2020

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2020-02-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ymgme.2020.02.006PMID 32224020
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency

  2020cited by this paper
• Mucopolysaccharidosis Type I

  2020cited by this paper
• A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease.

  2018cited by this paper
• Disease and subtype specific signatures enable precise diagnosis of the mucopolysaccharidoses

  2018cited by this paper
• Long-Term Galsulfase Treatment Associated With Improved Survival of Patients With Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): 15-Year Follow-Up From the Survey Study

  2018cited by this paper
• Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment.

  2017cited by this paper
• Measurement of Elevated Concentrations of Urine Keratan Sulfate by UPLC-MSMS in Lysosomal Storage Disorders (LSDs): Comparison of Urine Keratan Sulfate Levels in MPS IVA Versus Other LSDs.

  2016cited by this paper
• Clinical course of sly syndrome (mucopolysaccharidosis type VII)

  2016cited by this paper
• Recombinant, truncated B. circulans keratanase-II: Description and characterisation of a novel enzyme for use in measuring urinary keratan sulphate levels via LC-MS/MS in Morquio A syndrome.

  2015cited by this paper
• Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study

  2014cited by this paper
• Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy syndrome)—10‐year follow‐up of patients who previously participated in an MPS VI survey study

  2014cited by this paper
• Mucopolysaccharidoses

  2013cited by this paper
• Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.

  2012cited by this paper
• Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment.

  2011cited by this paper
• Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

  2011cited by this paper
• Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers

  2011cited by this paper
• Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I

  2009cited by this paper
• Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase.

  2008cited by this paper
• Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.

  2008cited by this paper
• A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.

  2007cited by this paper
• Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human α-l-Iduronidase (Laronidase)

  2007cited by this paper
• Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.

  2007cited by this paper
• A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).

  2007cited by this paper
• Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses - an evaluation

  2007cited by this paper
• Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.

  2006cited by this paper
• A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

  2006cited by this paper
• Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.

  2005cited by this paper
• Minimal Clinically Important Differences in the Six-Minute Walk Test and the Incremental Shuttle Walking Test

  2005cited by this paper
• Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux–Lamy syndrome)

  2005cited by this paper
• Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase

  2005cited by this paper
• Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

  2004cited by this paper
• Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

  2004cited by this paper
• Biodistribution, Kinetics, and Efficacy of Highly Phosphorylated and Non-phosphorylated β-Glucuronidase in the Murine Model of Mucopolysaccharidosis VII*

  2001cited by this paper
• Enzyme-replacement therapy in mucopolysaccharidosis I.

  2001cited by this paper
• Analytical method for keratan sulfates by high-performance liquid chromatography/turbo-ionspray tandem mass spectrometry.

  2001cited by this paper
• Active site mutant transgene confers tolerance to human β-glucuronidase without affecting the phenotype of MPS VII mice

  2001cited by this paper
• Advantages of Using Same Species Enzyme for Replacement Therapy in a Feline Model of Mucopolysaccharidosis Type VI*

  1999cited by this paper
• Enzyme Replacement in Murine Mucopolysaccharidosis Type VII: Neuronal and Glial Response to β-Glucuronidase Requires Early Initiation of Enzyme Replacement Therapy

  1999cited by this paper
• Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

  1997cited by this paper
• Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation.

  1997cited by this paper
• Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI.

  1997cited by this paper
• Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.

  1996cited by this paper
• Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

  1996cited by this paper
• Enzyme Replacement with Recombinant β-Glucuronidase in Murine Mucopolysaccharidosis Type VII: Impact of Therapy during the First Six Weeks of Life on Subsequent Lysosomal Storage, Growth, and Survival

  1996cited by this paper
• Enzyme replacement in a canine model of Hurler syndrome.

  1994cited by this paper
• The Mucopolysaccharidoses

  1976cited by this paper
• [Mucopolysaccharidoses].

  1969cited by this paper

• Advances in glycosaminoglycan based diagnostic strategies for mucopolysaccharidoses

  2026cites this paper
• Quantification of keratan sulfate in biofluids by validated HPCE-LIF: application to Morquio syndrome.

  2025cites this paper
• Efficacy and safety of a biosimilar laronidase versus the reference laronidase in patients with mucopolysaccharidosis type I

  2025cites this paper
• Associations between urinary glycosaminoglycans and onset of acute respiratory distress syndrome in sepsis patients: a prospective exploratory study

  2025cites this paper
• Role of Biomarkers in Diagnosing Disease, Assessing the Severity and Progression of Disease, and Evaluating the Efficacy of Therapies

  2025cites this paper
• N-glycan-modified α-L-iduronidase produced by transgenic silkworms ameliorates clinical signs in a Japanese macaque with mucopolysaccharidosis I

  2025cites this paper
• LYSOSOMAL STORAGE DISEASES AND CARDIOVASCULAR SYSTEM (REVIEW ARTICLE)

  2025cites this paper
• Management of mucopolysaccharidosis type I using enzyme replacement therapy: Egyptian experience

  2025cites this paper
• Specific GAG ratios in the diagnosis of mucopolysaccharidoses

  2024cites this paper
• Glycan-specific molecularly imprinted polymers towards cancer diagnostics: merits, applications, and future perspectives.

  2024cites this paper
• Structural Parameters of the Brain and Bone Structures of the Head and Neck in Patients with Various Types of Mucopolysaccharidoses According to Magnetic Resonance Imaging of the Brain

  2024cites this paper
• A novel graphene oxide‐based fluorescence method for detection of urine glycosaminoglycans

  2024cites this paper
• Disease characteristics, effectiveness, and safety of vestronidase alfa for the treatment of patients with mucopolysaccharidosis VII in a novel, longitudinal, multicenter disease monitoring program

  2024cites this paper
• Biomarkers for gene therapy clinical trials of lysosomal storage disorders.

  2024cites this paper
• Macroglossia in endocrine and metabolic disorders: current evidence, perspectives and challenges.

  2024cites this paper
• Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review

  2024cites this paper
• Urinary Glycosaminoglycans: Characterization and Quantification.

  2023cites this paper
• Identification of potential non-invasive biomarkers in diastrophic dysplasia

  2023cites this paper
• Growth patterns in patients with mucopolysaccharidosis VII

  2023cites this paper
• The Interplay of Glycosaminoglycans and Cysteine Cathepsins in Mucopolysaccharidosis

  2023cites this paper
• Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy

  2022cites this paper
• Results of 14-year-long Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II: Clinical Case

  2022cites this paper
• The transformation of drug development for the 21st century: Time for a change.

  2022cites this paper
• Hyaluronic acid promotes calcium oxalate crystal growth, crystal-cell adhesion, and crystal invasion through extracellular matrix.

  2022cites this paper
• Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study.

  2021cites this paper
• Comparing anti-aging hallmark activities of Metformin and Nano-PSO in a mouse model of genetic Creutzfeldt-Jakob Disease.

  2021cites this paper
• Mucopolysaccharidosis Type VI, an Updated Overview of the Disease

  2021cites this paper
• High-Throughput Liquid Chromatography–Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II

  2020cites this paper